Navigation Links
Wearing Mouth Appliance During Sleep may Help to Reduce Snoring

Researchers have found that wearing a mouth appliance designed to move the lower jaw forward can be an effective way to reduce snoring and improve sleep apnea symptoms.

The study found that patients who used the two-piece device, known as the Thornton Adjustable Positioner II (TAP II), experienced decreases in snores per hour and snoring loudness, along with a decrease in the percentage of palatal snoring events.

There was also a decrease in oxygen desaturation events (where oxygen levels are decreased by four percent or more from normal levels), according to the studys authors.

Based on these findings, the authors recommend further studies on the mechanisms of oral appliances, as well as the dynamic relationships within the pharyngeal airway in patients with obstructive sleep apnea and snoring problems.

Forty-five percent of normal adults snore at least occasionally, and 25 percent are habitual snorers. Problem snoring is more frequent in males and overweight people, and usually grows worse with age.

More than 300 devices are registered in the U.S. Patent and Trademark Office (USPTO) as cures for snoring.

The studys authors are Stephanie Stouder, DDS; Loren Jones, MD; Scott Brietzke, MD, MPH; and Eric A. Mair, MD, FAAP. They are associated with the U.S. Air Forces Wilford Hall Medical Center in San Antonio, Texas, US.

The stud appears in the journal Otolaryngology Head and Neck Surgery.


'"/>




Page: 1

Related medicine news :

1. Stroke Patients May Benefit By Wearing Cooling Helmets
2. Wearing High Heels May Be Dangerous To Health
3. Masking A Flu? – Wearing Masks, Only Way to Contain It’s Spred
4. Wearing No-line Bifocals Slows Myopia Progression in Some Children
5. Breast Cancer and Bra Wearing: Possibly Linked
6. Wearing Shorts, Sleeveless Clothes Could Make You Prone to Skin Cancer
7. Mouthwash as a weapon
8. Mouth Infection better handled with new discovery
9. Mouth wash samples to predict bone marrow transplant results
10. Under Stress? All You Need Is A Chocolate To Melt In Your Mouth
11. Dentists Recommend Kids Use Mouthguard To Protect Them When Doing Sports
Post Your Comments:
(Date:9/5/2008)...at triggers them, experts say , , FRIDA...he 36 million Americans who suffer from seasonal a...at is free from pollen and other allergens this fa...happen in the spring, they can be bothersome in ot...ging cities to live in are Greensboro, N.C., Green...
(Date:9/5/2008)... Tonight is a momentous,occasion as the three majo...utives, celebrities and prominent leaders in cance...nd Up to Cancer. This collaboration,featuring a o...n the three,networks -- ABC, CBS and NBC -- offers...on about cancer and the need to take action., For...
(Date:9/5/2008)...ht or obese at age 45 , , FRIDAY, Sept. ...adults will develop osteoarthritis of the knee by ...in middle age, a new study says. , A person,s ...his or her body-mass index (BMI) rose, according t...study. People who were of normal weight at age 18 ...
(Date:9/5/2008)...,s Annual Destination to Feature VelaShape. , ...eptember 5, 2008 -- http://www.americanlaser.com ..., the largest provider of laser hair removal and o...nnounces sponsorship of the STYLE360 show during N...serves as the alternative Fashion Week destination...
Breaking Medicine News(10 mins):Health News:No Place Safe From Allergies 2Health News:The Leukemia & Lymphoma Society: Standing Up to Cancer for 60 Years 2Health News:Almost Half of Adults Will Develop Knee Osteoarthritis by 85 2Health News:American Laser Centers Sponsors STYLE360 to Share the Skinny on Body Shaping 2
...disorders ahs been found out .This may lead to a m.... Researchers were able to develop a diagnostic te...most patients with myeloproliferative blood disord...y an overproduction of blood cells and can cause h...
...n found out that there is no association between a...ood -- and breast cancer. More than 43,000 women w...patients. The participants had their average daily...ence of an increased risk of breast cancer in the ...
...ced in the pancreas, but in the brain as well. Whe...ult can be brain cell death and subsequent develop...Alzheimer’s. The research was conducted in rats, a...s growth factors IGF I and IGF II were produced in...
... Association for Dental Research held in Baltimore...ts of a study// that says eating sugar-free yogurt...l bad odor or so called bad breath is caused by ha...ike hydrogen sulfide. The study revealed that volu...
Other Medicine News:
(Date:9/3/2008)...ional Vascular Disease Awareness Month, CHARLOTTE...rmaceuticals,LLC, a clinical-stage drug-developmen...ent of unmet medical needs, announced today that i...nical trial of its lead drug,candidate trans sodiu...5881,on the clinicaltrials.gov Website, is investi...
(Date:9/3/2008)... Multaq(R) (dronedarone) decreased the risk of,str...atrial flutter already adequately tre..., Sept. 3 /- The results of...tudy were presented today at,the clinical trial up...,congress 2008, in Munich, Germany. Previous resul...
(Date:9/3/2008)...firms Strong Evidence Pycnogenol(R) Lowers Joint, ...nts Following Cessation ...ire/ -- According to the Center for,Disease Contro...rthritis,is on the rise. A new study published in...als Pycnogenol(R), bark extract from the French ma...
(Date:9/2/2008)...wswire-FirstCall/ -- Forest Laboratories, Inc.,(NY...nnounced results from,two global Phase III studies...d anticholinergic for the treatment of patients wi...n both the ACCLAIM/COPD I&II,(AClidinium CLinical ...,Severe COPD Patients) studies, once-daily aclidin...
Breaking Medicine Technology:Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 2Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 3Study Shows Pine Bark Naturally Reduces Knee Osteoarthritis 4Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 2Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 3Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 4Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 5Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 6Rhode Island Hospital to study driving ability of cognitively impaired elders 8483 1Breast Cancer Imaging Study Indicates Breast Specific Gamma Imaging 28BSGI 29 Is a Strong Adjunct Imaging Modality to Mammography and Ultrasound 8479 1Breast Cancer Imaging Study Indicates Breast Specific Gamma Imaging 28BSGI 29 Is a Strong Adjunct Imaging Modality to Mammography and Ultrasound 8479 2Breast Cancer Imaging Study Indicates Breast Specific Gamma Imaging 28BSGI 29 Is a Strong Adjunct Imaging Modality to Mammography and Ultrasound 8479 3Stryker to Present at Investor Conferences 8474 1Stryker to Present at Investor Conferences 8474 2Medco Chooses AllPoints at Anson in Whitestown Indiana as Site for the Worlds Largest Most Advanced Automated Pharmacy 2271 1Medco Chooses AllPoints at Anson in Whitestown Indiana as Site for the Worlds Largest Most Advanced Automated Pharmacy 2271 2Medco Chooses AllPoints at Anson in Whitestown Indiana as Site for the Worlds Largest Most Advanced Automated Pharmacy 2271 3Medco Chooses AllPoints at Anson in Whitestown Indiana as Site for the Worlds Largest Most Advanced Automated Pharmacy 2271 4Medco Chooses AllPoints at Anson in Whitestown Indiana as Site for the Worlds Largest Most Advanced Automated Pharmacy 2271 5
...lot Study Demonstrates 50% Survival in Valortim-Tr..., March 29, 2007 - Medarex,Inc. (Nasdaq: MEDX), a...ene, Inc., a privately held biotechnology company ...measures, today announced,that Valortim, a fully h...eveloped for the prevention and treatment of anthr...
...LLEGEVILLE, Pa., March 30, 2007 /PRNewswire-FirstC... , Solvay,Pharmaceuticals, Inc. and Lundbeck A/S p...n international medical congress this,week. Safety...reatment for adult patients diagnosed with schizop... lipid profile, similar to,placebo. In addition, i...
Other Medicine Technology:Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 2Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 3Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 4Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 5Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 6Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic,Effect in New Primate Model of Established Anthrax Infection 7Safety Analyses of Clinical Data for Bifeprunox in Patients with,Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar,to Placebo 2Safety Analyses of Clinical Data for Bifeprunox in Patients with,Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar,to Placebo 3Safety Analyses of Clinical Data for Bifeprunox in Patients with,Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar,to Placebo 4Safety Analyses of Clinical Data for Bifeprunox in Patients with,Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar,to Placebo 5Safety Analyses of Clinical Data for Bifeprunox in Patients with,Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar,to Placebo 6
Inquire
...gra X-22 Series is up to 10 inches/ 25 cm thinner ... 11 rotors, the Allegra X-22 Series is the space-s... Features: Only 18 inches / 46 cm wide • 1... different ways to Spin 1.5 mL & PCR+ Tubes: 24-p...
...general purpose centrifuges offer high-volume vers...tions, making them ideal for a wide variety of lab...our- or six-place sealed swinging bucket rotor, mi...fered , Lare capacity (4 x 750 ml) accepts high-vo...
Inquire
Medicine Products: